InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT05463796
Status
Recruiting
Apply to this trial

Conditions

  • Adenomatous Hyperplasia
  • Adult Cancer Survivors
  • Barrett Esophagus
  • Benign Bone Lesions With Risk of Malignant Degeneration
  • Cancer Predisposition Syndrome
  • Cancer Risk
  • Cervical and Endocervical Carcinoma in Situ
  • Childhood Cancer Survivors
  • Cirrhosis
  • Colonic Dysplasia/Adenomata
  • Ductal/Lobular Carcinoma
  • Endometrial Intraepithelial Neoplasia
  • Giant Cell Tumor
  • Hematologic Malignancy
  • Hereditary Cancer Prediction
  • High Grade Prostatic Epithelial Neoplasia
  • High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ
  • High-risk Oral Precancerous Diseases
  • IARC Carcinogens
  • Lung Cancer
  • Lung; Node
  • Melanocytic Lesion, Adult
  • Nephrogenic Rests
  • Non Alcoholic Steatohepatitis
  • Non-Alcoholic Fatty Liver Disease
  • Osteochondroma
  • Pancreatic Precursor Lesions
  • Serous Tubal Intraepithelial Carcinoma
  • Smoking History
  • Spitz Nevus
  • Vulvar Intraepithelial Neoplasia

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Accepted

Interventions

  • Samples — OTHER
    Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues

Study Details

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.

Key Dates

Start date
Apr 25, 2023
Status verified
Aug 2025
Primary completion
Mar 25, 2027
Completion
Mar 25, 2032

Study Design

Enrollment
5,000 participants (estimated)

Arms

  • Arm: HEREDITARY RISK
    Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues
  • Arm: EXPOSED HIGH RISK
    Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues
  • Arm: PRECURSOR LESIONS
    Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues
  • Arm: FAMILY MEMBERS
    These family members will be identified by the patients participating in the study. Blood, buccal cells, or saliva or oral rinses will be collected in one of three ways from family members of patients (i) at the time of consent; (ii) via a mailed blood kit or saliva kit; or (iii) at a separate appointment scheduled by the consented participant

Primary Outcome Measure

Identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. [ Time Frame: 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Dana Farber Cancer InstituteBostonMassachusetts02115
Sapna Syngal, MD
[email protected]
617-632-5022
Sapna Syngal, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Dana Farber Cancer Institute· Boston, MA

Related Studies